Isoelectric focusing of alphafetoprotein in patients with hepatocellular carcinoma--frequency of specific banding patterns at non-diagnostic serum levels. by Ho, S. et al.
British Journal of Cancer (1996) 73, 985-988
© 1996 Stockton Press All rights reserved 0007-0920/96 $12.00 P
Isoelectric focusing of alphafetoprotein in patients with hepatocellular
carcinoma - frequency ofspecific banding patterns at non-diagnostic serum
levels
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PJ Johnson'
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Summary Serum levels of alphafetoprotein are raised in 60-80% of patients with hepatocellular carcinoma.
Although widely used as a serum marker, frequent false-positive results in patients with benign liver disease,
result in poor specificity. This occurs particularly when levels of alphafetoprotein fall between 50-500 ng ml ',
the so-called 'grey area'. Recent reports suggest that isoelectric focusing of alphafetoprotein demonstrates
certain bands that are more specific for hepatocellular carcinoma. Our aim was to determine whether the
apparent specificity of this new approach is gained at the expense of decreased sensitivity. Sera from 110
patients with a 'non-diagnostic' serum alphafetoprotein level (50-500 ng ml-') were examined by isoelectric
focusing and quantified by densitometric scanning. Ten patients with chronic liver disease and a raised serum
alphafetoprotein level (50-500 ng ml-'), but with no evidence of hepatocellular carcinoma, were also studied.
Isoelectric focusing revealed characteristic hepatocellular carcinoma bands (bands +II and +III) in 96%
patients overall, and 100% of those with levels of total alphafetoprotein greater than 100 ng ml -'. No such
bands were seen among ten subjects with cirrhosis but without hepatocellular carcinoma. Bands that are
characteristic of hepatocellular carcinoma (bands + II or +III) are seen in the great majority of hepatocellular
carcinoma patients; their absence makes a diagnosis of hepatocellular carcinoma extremely unlikely.
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In many parts of the world hepatocellular carcinoma (HCC)
represents a major public health problem. In Hong Kong the
annual incidence rate is about 40 per 100 000 in men, and in
our Joint Hepatoma Clinic we see between 5 and 15 new
cases each week. The median survival is less than 3 months
with very few patients surviving more than 1 year (Shiu et al.,
1990). Surgical resection offers the only hope of long-term
survival, but is an option for less than 10% of cases. This
may be because the tumour is already too large, metastatic
and/or hepatic function has been irreversibly impaired. These
observations emphasise the importance of early diagnosis.
Measurement of serum alphafetoprotein (AFP, reference
range <10 ng ml-') is one of the most widely used initial
tests and offers an opportunity to detect the tumour early
(Johnson and Williams, 1980; Lok and Lai, 1989). Serum
levels of greater than 500 ng ml-' are very strongly
suggestive of HCC. However, AFP concentrations between
10 and 500 ng ml-' lie in a 'grey area' since benign
conditions such as chronic hepatitis and cirrhosis can also
result in values within this range (Lok and Lai, 1989;
Johnson et al., 1978; Bloomer et al., 1975; Alpert and Feller,
1978; Okuda, 1986). Although there is no clear direct relation
between serum AFP levels and tumour size, in general, small
tumours tend to have lower levels of AFP that often fall
within the 'grey area' (Sawabu and Hattori, 1987). Since it is
these small tumours that are particularly important to detect
with a view to surgical resection, levels within this range pose
a major practical problem. Thus, while serum AFP is a useful
serum marker, the poor specificity for HCC at low levels
severely limits its practical application.
Several approaches have been used to increase the
specificity of AFP as a test for HCC. If levels continue to
increase, this is good evidence of HCC development.
Conversely, if levels fall or fluctuate then HCC is less likely
(Lok and Lai, 1989). However, by the time a confident
diagnosis is arrived at, the tumour may be too large for
resection. A more sophisticated approach is to distinguish
between the different AFP variants based on their differing
carbohydrate moieties (Yoshima et al., 1980; Yamashita et
al., 1983; Krusius and Ruoslahti, 1982; Aoyagi et al., 1993;
Tekata, 1990). Several groups have reported that AFP
originating from HCC and that from chronic liver disease
have different lectin-binding capacities (Taketa et al., 1983;
Du et al., 1991; Sato et al., 1993). More recently, it has been
suggested that, by using isoelectric focusing (IEF) of AFP,
certain banding patterns can be detected which are highly
specific for HCC even at low concentrations of AFP (Burditt
et al., 1994). However, the number of patients studied was
small, the various bands were not quantified and only five
variants were recognised. We now describe the distinctive
patterns of AFP variants as detected by IEF in a much larger
group of patients with moderately raised AFP levels, using a
more sensitive and quantitative method. This analysis allows
estimation of the sensitivity of the test and its value in
excluding HCC in patients with chronic liver disease and
raised AFP levels.
Patients and methods
Between February 1992 and October 1994, 924 patients with
HCC were referred to our clinic. Of these, 154 (16.7%) had a
'non-diagnostic' serum alphafetoprotein level (50-
500 ng ml-'). Stored serum samples, collected at the time
of first referral to our clinic, (always within 1 month of
presentation) were available from 110 patients for AFP
analysis. In 86 of these the diagnosis was histologically
confirmed; in 24 a histological diagnosis was not established
because the patient was in overt liver failure and it was
considered that biopsy would be dangerous and/or not
contribute to further management. Nonetheless, all these
patients had an ultrasound examination that was consistent
with a diagnosis of HCC and a raised AFP concentration,
albeit in the non-diagnostic range of 50-500 ng ml-' and, in
most cases, a hepatic angiogram. These investigations, in
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combination with a positive test for the hepatitis B surface
antigen (HBsAg) in 19 (79%), evidence of cirrhosis in 12
(50%), and typical presentation in a high incidence area, all
suggest that the diagnosis of HCC was correct in the great
majority of non-histologically confirmed cases. All sera
studied by IEF were surplus to requirements after routine
AFP estimation for clinical indications.
We also studied ten patients with chronic liver disease who
had a raised AFP level (50-500 ng ml-') in the same range
as the HCC patients. These samples were not contemporary
with those from the HCC patients. Rather, they came from a
serum bank gathered from patients with cirrhosis all ofwhom
had been followed up for at least 2 years, during which
period they had failed to reveal any evidence of the
development of HCC. However, we should stress that these
data are provided by way of illustration and it was not the
aim of the present study to assess the specificity of the test.
We also had the opportunity to study two additional
patients, both known carriers of HBsAg, who presented to us
with serum AFP levels of 8000 and 3400 ng ml-'. In neither
could any evidence of tumour be detected after detailed
investigation with ultrasonography, hepatic angiogram and
computed tomography. In the first patient, the total AFP
level fell to within the reference range during the follow-up
period of 8 months. In the second patient, levels fell to
100 ng ml-' over 6 months follow-up.
Measurement of AFP and its variants
Sera were separated and stored at -70°C before assay for
total AFP by a microparticle enzyme immunoassay (MEIA;
Abbott Laboratories, Chicago, USA). Isoelectric focusing of
AFP was based on the method of Burditt et al. (1994) with
modifications as previously described (Johnson et al., 1995).
Briefly, protein samples were focused in 1.5 mm-thick agarose
gel of size 100 x 125 mm containing 1% agarose (IEF grade
Type VIII, Sigma), 5% sorbitol, 10% glycerol and 2%
ampholytes pH 4.5-5.4 (Pharmalyte, Pharmacia). Samples
containing 0.1 to 1.0 ng of AFP in 2 ,ul were applied directly
to the gel and allowed to diffuse into the gel for 10 min.
Isoelectric focusing was done in flat bed apparatus (model
FBE 3000, Pharmacia) at a constant temperature of 10°C
regulated by a refrigerated circulation bath (RCB 500,
Hoefer). Initially focusing was carried out at 1500 V for
30 min followed by 2000 V for 1 h. The proteins were
transferred to nitrocellulose membrane (Hybond-ECL,
Amersham) by blotting for 80 min. The membrane was
treated with 2% skimmed milk (Carnation non-fat milk
powder) to block protein binding sites. Incubation with
polyclonal rabbit anti-human AFP conjugated with horse-
radish peroxidase (Dako) diluted 1: 200 with TBS containing
2% skimmed milk was carried out at room temperature with
shaking for about 100 min. After washing with TBS,
enhanced chemiluminescence detection system (ECL, Amer-
sham) and Hyperfilm-ECL (Amersham) were used to make
the protein bands visible. The protein bands were quantified
as a percentage of the total using a laser densitometer
(Ultroscan XL, Pharmacia).
Band nomenclature
Burditt et al. (1994) described four bands in patients with
HCC and numbered these I IV. Band I was common to all
forms of chronic liver disease; band II appeared in all HCC
sera and band III in about 20%. These latter two bands were
not present in chronic liver disease sera. Using the present
technique nine bands are detectable. We have therefore
proposed a new nomenclature (Johnson et al., 1995). The
anodal bands before the main band are called -(minus) V to
-(minus)I; the cathodal bands are +(plus) I to +(plus) IV;
+(plus) II and + (plus) III are the bands that appear specific
for HCC. In order to assess the potential importance of our
test we also recorded the AFP levels of all HCC patients
presenting to our clinic over the same period. This allowed
the calculation of the percentage of patients who had AFP
levels in the range 50-500 ng ml-' at the time of
presentation.
Results
The distribution of AFP levels among the 924 patients is
shown in Table I. It is apparent that 16.7% fell within the
range 50-500 ng ml-l. A further 11.5% fell in the range 10-
49 ng ml- .
The approach to the classification of the various patterns
is outlined in Table II and the bands -V to -I are highly
variable and are not considered for this purpose. Despite the
apparently large number of patterns, the great majority of
patients have the easily recognisable pattern of HI or H2.
The distribution of the different AFP isoforms in each of the
groups (HI to H8, Figure 1), expressed as a percentage of the
total AFP, are shown in Tables III and IV. Of the 86 patients
with histologically proven HCC, 81 had band +II. This
represented between 1.9% and 80.3% (median 20%) of the
total AFP. In addition, 15 had band +III (Table III). Four
patients, all of whom had low AFP levels (65, 76, 81 and
88 ng ml-') had no characteristic HCC bands. Results in
patients with clinically diagnosed HCC were similar except
that there were two further types of band pattern (H7 and
H8) each exhibited by one patient with a predominant +IV
(Table IV). Thus the overall sensitivity (presence of band +II
and/or band +III) is greater than 95%. For those with total
AFP levels of greater than 100 ng ml-', the figure is 100%.
In contrast, the ten patients with chronic liver diseases and
AFP levels in the range 50-500 ng ml-', but without HCC
all had band + I together with some of the anodal (negative)
bands. None had any of the characteristic HCC bands
(Figure 2). In the two patients with grossly elevated AFP and
no evidence of HCC, the + II to +III bands characteristic of
HCC were also not detectable on IEF of their serum after
dilution to approximately 500 ng ml-l so that the mass of
AFP applied fell within the range 0.1-1.0 ng.
Discussion
One major limitation to the use of AFP for the diagnosis of
HCC is the high frequency of false-positive results,
Table I Distribution of AFP levels in the 924 patients with HCC
seen over the study period






Table H Classification of banding patterns. Bands -V to -I are
very variable and not considered for the purpose of classification.
HI and H2 are the major forms and either band + II or +III is seen
in all but four patients
No. of Band
patients -V to -I +I +II +III +IV pattern
77 +/0 + + 0 0 HI
17 + 0 + + 0 H2
2 + + + + 0 H3
1 + 0 0 + 0 H4
7 + 0 + 0 0 H5
4 + + 0 0 0 H6
1 + 0 0 + + H7
1 + 0 + + + H8AFP in hepatocellular carcinoma
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Figure 1 Variations in the IEF banding patterns ofAFP in patients with HCC. Types HI -H8 refer to patterns quantified in Table
II. The HI pattern is by far the most common accounting for 70% of cases.
Table m Distribution of banding patterns in the 86 patients with
histologically confirmed HCC. Figures refer to the percentage of
total AFP in individual patients
No. of Band
patients -V to -I +I +II +III +IV pattern
64 0-81.8 12.4-84.6 1.9-52.7 0 0 Hl
12 5.0-62.4 0 27.6-80.3 5.8-44 0 H2
2 9.3-28.6 3.2-60.5 25.0-55.0 5.2- 13.2 0 H3
1 20.0 0 0 80.0 0 H4
3 23.9-68.1 0 31.9-76.1 0 0 H5
4 44.7-77.5 22.5-55.3 0 0 0 H6
Table IV Distribution of banding patterns in the 24 patients with
clinically diagnosed HCC. Figures refer to the percentage of total
AFP in individual patients
No. of Band
patients -V to -I +I +1I +III +IV pattern
13 3.2-42.1 30.8-76.8 3.1-38.2 0 0 HI
5 32.1-62.2 0 25.9-40.9 11.3-27.6 0 H2
4 18.1-40.1 0 59.9-80.9 0 0 HS
1 39.5 0 0 30.0 31.0 H7
1 53.7 0 4.5 4.5 37.0 H8
particularly in the range 10-500 ng ml-l. This leads to a low
specificity. The preliminary results by Burditt et al. (1994),
and the findings reported here make a prima facie case that
the current approach does indeed increase the specificity of
'total' AFP. As discussed below, the precise figure for
specificity still needs to be calculated in a prospective study
and in a relevant clinical setting. The present study shows
that, coincident with the increased specificity of this new
approach, there is only a very small decrease in sensitivity. By
definition, since we are only dealing with AFP positive HCC
cases, 'total' AFP must be 100% sensitive. It is most
encouraging that the current test remains 100% sensitive
above 100 ng ml-' and greater than 95% sensitive even when
the range from 50-100 ng ml-' is included.
In this large series, over 95% of HCC patients with AFP
levels between 50 and 500 ng ml-1 have characteristic HCC
bands detected by isoelectric focusing. The most frequent
band was band +II, seen in all but six cases. Further patterns
can be recognised by the occasional additional presence of
bands + III or + IV. Although not reported in detail here, it is
our experience that a similar distribution of bands is seen in
patients with higher AFP levels. We can thus conclude that in
the absence of one ofthe characteristic bands (+ II and +III)
in a patient with an AFP of >50 ng ml-', the presence of
HCC is extremely unlikely. The absence of HCC bands in the
two patients with grossly raised AFP, but no detectable HCC,
also appears to support this contention.
On the other hand, the precise significance of the presence
of a 'specific band' is, as yet, uncertain. However, in none of
our control group was any ofthese bands detected in patients
with confirmed uncomplicated chronic liver disease. This,
together with the original small study by Burditt et al. (1994),
suggests that the test is likely to be highly specific. Although
Burditt et al. (1994) reported a specificity of 85%, the number
of cases was small, the test was not carried out in a practical
clinical setting and the technique was different. To determine
the precise figure for specificity of our current assay is a more
difficult problem and the present study was not designed with
this aim in mind. The difficulty arises because patients with
cirrhosis may develop the characteristic bands several months
before there is any clinical suspicion or physical evidence (i.e.
imaging) of HCC (Burditt et al., 1994). Thus a true and
accurate estimate of specificity in a practical clinical setting
demands longer term follow-up ofthose subjects with chronic
liver disease who are found to have the putative HCC
'specific' bands. We are currently undertaking such a study.
Over 500 patients with apparently non-malignant chronic
liver disease have been screened for AFP and those with
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screened) are being followed up prospectively. This study will
allow a precise estimate of the specificity of the test in a
clinically important situation.
Our data on the distribution of AFP levels at the time of
presentation shows that over 15% of patients fall within the
range 50-500 ng ml-' at the time of symptomatic presenta-
tion. We are currently attempting to extend the detection limit
to below 50 ng ml-' by either doubling the sample volume to
4 p1 or by concentrating the serum sample before IEF to give a
mass of0.1 - 1.0 ng in 2pl. Preliminary results areencouraging
and we can consistently detect characteristic AFPbands in sera
with total levels as low as 30 ng ml-'. Ifsuch endeavours prove
successful wehave the prospect ofa simple test that canexclude
HCC over the entire 'grey area' of 10-500 ng ml-', a range
that as we show here, encompasses 28% ofHCC patients. This
encourages us to believe that it may be a useful screening
procedure either in whole populations in high HCC incidence
areas, or among high-risk groups, such as patients with
cirrhosis or chronic carriers ofHBsAg.
IEF is a widely used analytical technique that is recognised
to be one of the most sensitive in separating isoforms of
proteins. In classic early studies, Alpert et al. (1972) and
Purves et al. (1970) reported the detection of two distinct
bands in fetal and HCC sera with isoelectric points of4.8 and
5.2. As more sensitive techniques have been developed, so
more bands have been detected (Lester et al., 1978). Using a
blotting method up to nine bands are now recognised in fetal
sera (Sittenfeld and Moreno, 1988), a finding consistent with
our own results (Johnson et al., 1995). The molecular basis of
this charge heterogeneity is most likely attributable to post-
synthetic modifications of the carbohydrate moiety of the
protein (Smith and Kelleher, 1980). Although early work
suggested that such modifications involved mainly sialic acid
residues (Alpert et al., 1972; Purves et al., 1970), subsequent
studies showed that although the pattern of heterogeneity
was indeed altered after incubation with neuraminidase, it
was not abolished (Sittenfeld and Moreno, 1988; Smith and
Kelleher, 1980). The potential for variation in these isoforms
to be ofdiagnostic significance received limited attention until
the study by Burditt et al. (1994). More attention had been
paid to distinguishing between AFP variants based on their
lectin-binding characteristics. The biochemical basis for these
changes has been described in detail (Yoshima et al., 1980;
Yamashita et al., 1983; Krusius and Ruoslahti, 1982; Aoyagi
et al., 1993; Tekata, 1990).
In the mouse, (where most of the charge heterogeneity in
AFP is explained by differences in sialic acid content)
appropriate alterations in the activity of sialyltransferase
during fetal life have been documented (Zimmerman and
Maddappaly, 1973). However, as implied above the situation
is probably more complex in man. Here the variation in
carbohydrate structure of AFP (and other glycoproteins
secreted in patients with HCC) may result from the
expression of several different glycosyltransferases (Du et
al., 1990; Hutchinson et al., 1991). It is possible that the
variants recognised by the current technique follow the re-
expression of various fetal glycosyltransferases by malignant
hepatocytes, which are not normally expressed during adult
life.
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